Sky-high drug prices for rare diseases show why Orphan Drug Act needs reform
- Written by Dana Goldman, Director, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California

When Marathon Pharmaceuticals announced in February it would market a drug for treating Duchenne muscular dystrophy for US$89,000 a year, the negative reaction was so intense that the company immediately suspended the rollout. (On Thursday, March 16, Marathon announced it was...
Read more: Sky-high drug prices for rare diseases show why Orphan Drug Act needs reform